Robust Multiplex Mass Spectrometric Assay for Screening Small-Molecule Inhibitors
A robust multiplex mass spectrometric assay for screening small-molecule inhibitors of CD73 with diverse inhibition modalities. Credit: Gejing Deng
A new original research article in SLAS Discovery presents a fast, sensitive, and robust methodology for screening small molecule inhibitors against CD73/Ecto-5'-Nucleotidase, a promising target for developing anti-cancer drugs.
The methodology described by authors Gejing Deng (Sanofi) et al., uses multiple stable isotope-labeled substrates for carrying out CD73 reactions followed by sample pooling then simultaneously quantifying multiple reaction products using ultra-fast RapidFire-MS/MS.
In contrast to other optical based methodologies, this methodology allows identifying molecules with diverse inhibition modalities and characterizing inhibitors using both recombinant CD73 and CD73+ cells.
This article has been republished from materials provided by SLAS. Note: material may have been edited for length and content. For further information, please contact the cited source.
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Simple Sugar Prevents Neurodegeneration in Lysosomal Storage DiseaseNews
New therapeutic approach may one day delay neurodegeneration typical of a disease called mucopolysaccharidoses IIIB (MPS IIIB)READ MORE